Aytu Biopharma (AYTU) Operating Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Operating Expenses data on file, last reported at $11.7 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 12.31% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $51.8 million, a 5.53% increase from a year earlier, with the FY2025 full-year figure at $53.7 million, up 5.95% from the prior year.
• Operating Expenses for Q1 2026 stood at $11.7 million, up from $11.6 million in the prior quarter.
• Over the last five years, Operating Expenses for AYTU reached as high as $66.1 million in Q1 2022 and fell as low as $10.4 million in Q1 2025.
• Historically, Operating Expenses has averaged $18.8 million across 5 years, with a median of $13.3 million in 2024.
• Across the five-year window, Operating Expenses surged 2179.55% in 2022 and slumped 67.78% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $24.2 million in 2022, then tumbled by 52.58% to $11.5 million in 2023, then increased by 8.94% to $12.5 million in 2024, then decreased by 7.11% to $11.6 million in 2025, then rose by 0.6% to $11.7 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $11.7 million in Q1 2026, $11.6 million in Q4 2025, and $10.7 million in Q3 2025.